ENO2 and asthma: IFN-β treatment led to a significant decrease in viral load at 2d compared to the untreated samples in both asthma groups with 4.22-fold decrease in the SE group (p=4.81e-04) compared to a 3.39-fold decrease in the NSE group (p=1.7e-04) (Figure 3A).